Sign in
DMRA Stock Price, Chart, Stats & News
Damora Therapeutics, Inc.
Save
1.50B
Market cap
–
Current P/E
–
Forward P/E
DMRA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.01% |
ROA | -147.58% |
ROE | -147.05% |
D/E | 0.21x |
Interest coverage ratio | – |
DMRA valuation
P/E | – |
P/S | – |
P/B | 5.08x |
P/CF | – |
P/FCF | – |
P/OCF | – |
PEG | -0.27x |
EV multiple | -130.28x |
About
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2.
Similar securities
Based on sector and market capitalization
Report issue